学术报告- Nanopore technology -“Small” platforms enabling “big” changes in disease detection

报告题目： Nanopore technology -“Small” platforms enabling “big” changes in disease detection

报告人：Tony Y. Hu Ph.D. Assistant Professor

时间：2015年4月20日周一下午2:30

地点：15教学楼110会议室

附主讲人简历：

Dr. Tony Hu currently serves as an assistant professor in the Department of Nanomedicine at the Houston Methodist Research Institute and the director of the PeptidomicNanoengineering Core at Houston Methodist Hospital. He is also an assistant professor in the Department of Cell and Developmental Biology at Weill Cornell Medical College of Cornell University (New York). He received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. Dr. Hu brings a diverse background that combines Biochemistry, Mass Spectrometry, Nanofabrication, and Biomedical Engineering. He has been working on the development and engineering of nanoporous-silica devices, including their application in discovery and validation of biomarkers for years. Dr. Hu has published more than 30 journal papers, and holds 5 U.S. patents (issued and pending) on these subjects since his facultyship starting from 2011. Dr. Hu also contributed four book chapters on the nanomedicine field, and gave more than 20 invited presentations in many major scientific conferences, seminars around the world. His work has been reported by ABC TV, AACC, Chemical&Engineering News, Science Translational Medicine, Nanowok, Science Daily and etc. Dr. Hu received the Gates Foundation Grand Challenge Explorations Award (2012), Virginia and Ernest Cockrell Junior Faculty Award (2012), HMRI President Award (2013), Golfer Against Cancer Award (2014), Kostas Cardiovascular Nanomedicine Award (2014) and Cornerstone Award (2015). His in-depth knowledge of multiplex-detection method development, which is for sample processing, mass spectrometry, biomarker identification and validation, ideally positions him in a leading role to ensure optimal progress toward the clinical translation of a platform for improved and comprehensive analysis of blood-based biomarkers, with potentially broad clinical applications.

Nanotechnology is a promising tool to improve diagnosis, assess treatment efficacy and design personalized therapies with minimal invasiveness. Dr. Hu's research team is developing integrated mesoporous material based microsystems, semiconductor chips and nanotechnologies for imaging, sensing and regulating cellular processes critical to healthcare, and environmental and defense applications. His current research focuses on developing tools and methods to understand and regulate complex biological networks that are critical to the development of disease, and developing nano-micro fabricated sensors for biomaterial characterization that can be used to improve pre-cancerous lesion detection. Nano-Micro scale science, information, and biomedicine are integrative components of his research, and are used in combinaion with advanced engineering tools to facilitate biomedical studies and develop robust diagnostics for global health initiatives.